Document:

License Agreement dated August 27, 2008

 Exhibit 10.18 
 LICENSE AGREEMENT 
 This License Agreement
(the “Agreement”) is made and entered into by and between Rodan & Fields, LLC, a California limited liability company with its principle place of business at 111 Maiden Lane, Suite 600, San Francisco, CA 94108
(“Licensee”) and Helix BioMedix, Inc., a Delaware, United States corporation with its principle place of business at 22118 20th
Avenue SE, Suite 204, Bothell, WA 98021 (“Licensor”). 
 1. Certain Definitions. 
 1.1 An “Affiliate” of a party means an entity directly or indirectly controlling, controlled by or under common control
with that party, where control means the ownership or control, directly or indirectly, of more than 50% of all of the voting power of the shares (or other securities or rights) entitled to vote for the election of directors or other governing
authority, as of the date of this Agreement or hereafter during the term of this Agreement; provided that such entity shall be considered an Affiliate only for the time during which such control exists. 
 1.2 “Disclosing Party” means a party hereto that discloses its Proprietary Information to the other party. 
 1.3 “Distribution Channel” means Licensee’s direct marketing and sales distribution channel and related Internet and
retail sales distribution channels. 
 1.4 “Market” means the cosmetic- and over-the-counter- personal care
products market. 
 1.5 “Peptides” means Licensor’s proprietary bioactive peptides. 
 1.6 “Products” means final, marketable cosmetic or over-the-counter personal skin care formulations developed by Licensee
hereunder. 
 1.7 “Product Unit” means an individual Product stock keeping unit (SKU). 
 1.8 “Proprietary Information” of a Disclosing Party means the following, to the extent previously, currently or
subsequently disclosed to the other party hereunder or otherwise: information relating to the properties, composition, or structure of technology or the manufacture or processing thereof or machines therefor or to the Disclosing Party’s
business (including, without limitation, names and expertise of employees and consultants, know-how, formulas, processes, ideas, inventions (whether patentable or not), schematics, and other technical, business, financial, customer and product
development plans, forecasts, strategies and information). In particular, but without limitation, the Peptides and their properties, composition, and structure, and the Technology, are Proprietary Information of Licensor. 
 1.9 “Proprietary Rights” means patent rights, copyrights, trade secret rights and all other intellectual and industrial
property rights of any sort. 
 1.10 “Receiving Party” means a party hereto that receives Proprietary
Information of the other party. 
 Confidential treatment has been requested for portions of this exhibit. This exhibit omits the information subject to
the confidential treatment request. Omissions are designated as ***. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  

 1 

 1.11 “Technology” means Licensor’s Pip3TM Technology, as
described in Exhibit A. 
 2. License Grant. Subject to all the terms and limitations of this Agreement, Licensor hereby grants
Licensee a non-exclusive worldwide license, without the right of sublicense, under Licensor’s Proprietary Rights in the Technology solely for (i) use of the Technology with the Peptides incorporated into Products developed by Licensee
hereunder and (ii) marketing, selling and distributing the Products in the Market through the Distribution Channel. As a limitation on the scope of this license and as a covenant of Licensee, no Peptides or Technology may be marketed, sold,
licensed or distributed directly or indirectly by or under the authority of Licensee other than as formulated into Products developed by Licensee as provided hereunder. 
 3. Licensor Scientific Support Services. Licensor will provide to Licensee reasonable access to Licensor’s laboratory facilities and assistance by Licensor’s scientific personnel in connection with
technology studies and marketing support technology claims with respect to the Products and the Technology. 
 4. Product Development,
Launch and Marketing Efforts. Subject to Section 6.1 and the other provisions in this Agreement, Licensee will use best commercial efforts to develop Products using the Technology, to launch ***, and to market the Products in accordance
with the terms and conditions of this Agreement. Licensor agrees to cooperate with Licensee’s efforts to develop and market Products using the Technology and to provide scientific and/or technical assistance to Licensee upon Licensee’s
reasonable request. 
 5. Marks and Marking. Except to the extent otherwise decided by Licensor, all promotional materials and
packaging of Licensee relating to the subject matter of this Agreement will include (in easily readable, non-obscured type that is of reasonable size in light of the other names and notices) any reasonable patent, patent application or other
proprietary markings and notices of Licensor or its licensors. Upon reasonable written notice but no more than once every 12 months during which this Agreement is in effect, Licensor will have the right to audit Licensee’s promotional
materials, packaging or statements regarding the Products or any mark, name or designation of Licensor or its licensors to ensure compliance with terms of this Section 5. Except as expressly provided herein, Licensee has no right or license
with respect to, and will not use or register, any mark, name or designation of Licensor or its licensors anywhere in the world, and use of any Licensor mark and any related goodwill will inure to Licensor’s benefit. 
 6. Royalties; Audit. 
 6.1 In lieu of paying Licensor an up-front license fee, Licensee agrees to spend a minimum of *** on a controlled study for the purpose of validating the benefits of the Technology, which study shall be completed within 12 months of the
Effective Date of this Agreement, and to promptly provide Licensor with copies of all documents and reports prepared in connection with such study, subject to the confidentiality provisions set forth in this Agreement. Nothing in this Agreement
shall obligate Licensee to sell or market Products if Licensee, in its reasonable discretion, determines that the controlled study referenced in this Section 6.1 does not validate the benefits of the Technology. 
 6.2 Subject to the provisions of Section 6.1 above, Licensee will pay Licensor a royalty of *** from the sale of each Product Unit.
In the event that multiple Product Units are distributed in kits or packages, such royalty will be payable with respect to each individual Product Unit contained in any such kit or package. ***. 
  

	***	Confidential treatment requested 

 2 

 6.3 Royalties shall be paid within 45 days of the end of each calendar quarter with
respect to royalty-bearing sales occurring in that quarter and will be accompanied by a statement indicating the associated sales and royalties payable, itemized by Product. Royalties shall be paid by Licensee in U.S. dollars. Any amount payable
hereunder that is not paid on the date that it becomes due will bear interest, calculated based on the number of days such payment is late and compounded monthly, at a rate of the lesser of (i) 1% per month or (ii) the maximum rate
permitted by applicable law. 
 6.4 Licensee shall keep and maintain detailed and accurate books and records with regard to
Product sales, royalties and the calculation thereof. Licensor or its representatives (or, at Licensor’s option, a reputable independent certified public accounting firm selected by Licensor) shall be entitled to review and audit such books and
records from time to time during normal business hours upon reasonable notice to Licensee and at Licensor’s expense; provided that Licensee will bear any such expense if the review or audit shows an underpayment of more than 5% for any quarter
or in the aggregate. 
 7. Nonsolicitation. During the term of this Agreement and for one (1) year thereafter, neither party will
solicit any employee, consultant or contractor of the other to leave the employ of the other. 
 8. Confidentiality. Each party
recognizes the importance to the other of the other’s Proprietary Information. In particular Licensee recognizes that the Peptides and Technology and other of Licensor’s Proprietary Information (and the confidential nature thereof) are
critical to the business of Licensor and that Licensor would not enter into this Agreement without assurance that such technology and information and the value thereof will be protected as provided in this Section 8 and elsewhere in this
Agreement. Accordingly, each party agrees as follows: 
 8.1 The Receiving Party agrees: (i) to hold the Disclosing
Party’s Proprietary Information in confidence and to take reasonable precautions to protect such Proprietary Information (including, without limitation, all precautions the Receiving Party employs with respect to its confidential materials);
(ii) not to divulge any such Proprietary Information or any information derived therefrom to any third person; (iii) not to make any use whatsoever at any time of such Proprietary Information except as expressly authorized in this
Agreement; and (iv) not to remove or export from the United States or reexport any such Proprietary Information or any direct product thereof (e.g., Peptides, Technology or Products) except in compliance with and with all licenses and approvals
required under applicable U.S. and foreign export laws and regulations, including without limitation, those of the U.S. Department of Commerce. Any employee, consultant or contractor given access to any such Proprietary Information must have a
legitimate “need to know” and shall be similarly bound in writing. 
 8.2 Without granting any right or license, the
Disclosing Party agrees that clauses (i), (ii) and (iii) of Section 8.1 shall not apply with respect to information the Receiving Party can document: (i) is in or (through no improper action or inaction by the Receiving Party or
any Affiliate, agent or employee) enters the public domain (and is readily available without substantial effort); or (ii) was rightfully in its possession or known by it prior to receipt from the Disclosing Party; or (iii) was rightfully
disclosed to it by another person without restriction; or (iv) was independently developed by it by persons without access to such information and without use of any Proprietary Information of the Disclosing Party. The Receiving Party must
promptly notify the Disclosing Party of any information it believes comes within any circumstance listed in the immediately preceding sentence and will bear the burden of proving the existence of any such circumstance by clear and convincing
evidence. In addition, the Receiving Party may make disclosures required by law, provided that the Receiving Party gives the Disclosing Party prompt written notice of such requirement prior to such disclosure, uses reasonable efforts to limit
disclosure and to obtain confidential treatment or a protective order, and has allowed the 

  

	***	Confidential treatment requested 

 3 

 
Disclosing Party to participate in the proceeding. Each party’s obligations under Section 8.1 will apply only to disclosures made during the term
of this Agreement; however, such obligations will continue indefinitely with respect to disclosures made during that period. 
 8.3 Within thirty (30) days following the termination of this Agreement, the Receiving Party will return to the Disclosing Party all Proprietary Information of the Disclosing Party and all documents or media containing any such
Proprietary Information and any and all copies or extracts thereof. 
 8.4 The Receiving Party acknowledges and agrees that
due to the unique nature of the Disclosing Party’s Proprietary Information, there can be no adequate remedy at law for any breach of its obligations hereunder, that any such breach may allow the Receiving Party or third parties to unfairly
compete with the Disclosing Party resulting in irreparable harm to the Disclosing Party, and therefore, that upon any such breach or any threat thereof, the Disclosing Party shall be entitled to appropriate equitable relief (without the posting of
any bond) in addition to whatever remedies it might have at law and to be indemnified by the Receiving Party from any loss or harm, including, without limitation, lost profits and attorney’s fees, in connection with any breach or enforcement of
the Receiving Party’s obligations hereunder or the unauthorized use or release of any such Proprietary Information. The Receiving Party will notify the Disclosing Party in writing immediately upon the occurrence of any such unauthorized release
or other breach. Any breach of this Section 8 will constitute a material breach of this Agreement. 
 9. Notification of
Infringement; Cooperation. If Licensee becomes aware of any product or activity of any third party that may involve infringement or violation of any Licensor patent or other Proprietary Right, then Licensee shall promptly notify Licensor in
writing of such actual or potential infringement or violation. Licensor may in its discretion take or not take whatever action it believes is appropriate in response to any actual or potential infringement or violation of a Licensor patent or other
Proprietary Right; if Licensor elects to take action, Licensee will fully cooperate therewith at Licensor’s expense, including joining as a party if necessary. 
 10. Effective Date, Term and Termination. 
 10.1 The Effective Date of this Agreement
shall be the latest of the dates shown by the signatures below. 
 10.2 This Agreement will remain in effect for three
(3) years from the Effective Date above unless terminated pursuant to this Section 10 or Section 6.1. This Agreement will automatically renew for successive one-year terms unless (i) Licensee provides notice of termination to
Licensor at least 60 days before the end of the then-current term; (ii) Licensor provides notice of termination to Licensee at least 180 days before the end of the then-current term; or (iii) Licensee fails to make total royalty payments
in the amount of *** by the end of the then-current term. 
 10.3 If a party materially breaches a material provision of this
Agreement, the other party may terminate this Agreement upon 30 days’ notice (or 10 days’ notice in the case of nonpayment) unless the breach is cured within the notice period. 
 10.4 If Licensee fails to launch a Product within 18 months of the Effective Date of this Agreement, this Agreement shall automatically
thereupon terminate. 
  

	***	Confidential treatment requested 

 4 

 10.5 In the event Licensee, in its reasonable discretion, determines that the controlled
study referenced in Section 6.1 does not validate the benefits of the Technology, Licensee shall have the right to terminate this Agreement upon thirty (30) days’ notice to Licensor. 
 10.6 In the event of any termination of this Agreement, all the rights and licenses granted Licensee under this Agreement shall terminate
and Licensor’s obligations to provide goods, services, facilities, technology or information shall cease but all other provisions of this Agreement will continue in accordance with their terms. 
 10.7 Neither party shall incur any liability whatsoever for any damage, loss or expenses of any kind suffered or incurred by the other
arising from or incident to any termination of this Agreement (or any part thereof) by such party which complies with the terms of the Agreement whether or not such party is aware of any such damage, loss or expenses. 
 10.8 Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain
available. 
 11. INCIDENTAL AND CONSEQUENTIAL DAMAGES. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY
WILL BE LIABLE UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT. THE LIMITATIONS IN THIS SECTION 11 SHALL NOT APPLY
TO BREACHES OF SECTION 8 (CONFIDENTIALITY) OR TO ACTIONS OF LICENSEE BEYOND THE SCOPE OF THE LICENSE GRANT HEREUNDER. THIS SECTION DOES NOT LIMIT LIABILITY FOR BODILY INJURY OF A PERSON. 
 12. LIMITATION OF OBLIGATIONS AND LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, LICENSOR WILL NOT BE LIABLE WITH
RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY FOR COST OF PROCUREMENT OF SUBSTITUTE GOODS, SERVICES, TECHNOLOGY OR RIGHTS OR FOR ANY AMOUNTS AGGREGATING IN EXCESS OF AMOUNTS PAID TO
IT HEREUNDER BEFORE THE CAUSE OF ACTION AROSE. THIS SECTION DOES NOT LIMIT LIABILITY FOR BODILY INJURY OF A PERSON. 
 13. Insurance.

 13.1 During the term of this Agreement, each party shall maintain commercial general liability insurance in amounts not
less than *** per occurrence and *** annual aggregate from an underwriter who has an A.M. Best rating of A-VII or better, and naming the other party as an additional insured. Such commercial general liability insurance shall include but not be
limited to contractual and product liability coverage. Licensee agrees that its general liability insurance shall include worldwide coverage prior to marketing or selling any Products outside of the United States. The liability policies required
under this Section 13 shall be written as primary and non-contributing to not in excess of any coverage the other party may choose to maintain. The minimum amounts of insurance coverage required under this Section 13 shall not be construed
to create a limit of a party’s liability hereunder. 
 13.2 Each party shall provide the other party with written
evidence of such insurance at any time during the term of this Agreement promptly upon the request of the other party. Each party shall provide the other party with written notice at least 30 days prior to any cancellation, non-renewal or material
change in such insurance. If a party does not obtain replacement insurance providing comparable 

  

	***	Confidential treatment requested 

 5 

 
coverage prior to the expiration of such 30-day period, the other party shall have the right to terminate this Agreement effective at the end of such 30-day
period without any additional waiting periods. 
 13.3 Each party shall maintain such commercial general liability insurance
beyond the expiration or termination of this Agreement during the period that any Products are commercially marketed, distributed or sold under this Agreement. 
 14. Compliance with Applicable Law. Licensee shall comply with and shall, upon reasonable prior notice by Licensor, demonstrate such compliance with, the U.S. Foreign Corrupt Practices Act and all applicable
export laws, restrictions, and regulations of any U.S. or foreign agency or authority, and shall obtain, and bear all expenses relating to, any necessary licenses and/or exemptions with respect to the export from the U.S. or elsewhere by Licensee or
its agents of any Peptide (or any product or material containing, incorporating or based on any Peptide) or any Technology or other technology or information it obtains or learns pursuant to this Agreement (or any direct product thereof).

 15. Independent Contractors. The parties are independent contractors and not partners, joint venturers or otherwise affiliated and
neither has any right or authority to bind the other in any way. 
 16. Assignment. The rights and obligations of the parties under
this Agreement may not be assigned or transferred (and any attempt to do so will be void), except that: (i) rights to payment of money may be assigned; and (ii) this Agreement and the rights and obligations hereunder may be assigned by
Licensor to an acquiror of all or substantially all of its assets, business or capital stock. 
 17. WARRANTY DISCLAIMER. EXCEPT AS
EXPRESSLY PROVIDED HEREIN, LICENSOR MAKES NO WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
 18. Indemnification. 
 18.1 By Licensee. Licensee shall at all times during the term of this Agreement and thereafter indemnify defend and hold Licensor
and its directors, officers, stockholders, employees, agents and affiliates (collectively, “Licensor Indemnitees”) harmless against any and all liabilities, losses, fines, penalties, damages, expenses of any kind whatsoever, including
legal expenses and reasonable attorneys’ fees (collectively, “Losses”) that arise out of any claim, action, demand, suit, or proceeding brought against a Licensor Indemnitee by any third party to the extent attributable to or
resulting from Licensee’s development, manufacture, marketing, sale, distribution, use or consumption of Licensee’s products or services (including, without limitation, any products that contain, incorporate or are based on Peptides and/or
the Technology). Licensee’s indemnification obligations under this Section 18.1 shall not apply to any Losses to the extent that they are directly attributable to the grossly negligent activities or intentional misconduct of any of the
Licensor Indemnitees. 
 18.2 By Licensor. Licensor shall at all times during the term of this Agreement and thereafter
indemnify defend and hold Licensee and its directors, officers, stockholders, employees, agents and affiliates (collectively, “Licensee Indemnitees”) harmless against any and all Losses, (as defined above) that arise out of any claim,
action, demand, suit, or proceeding brought against a Licensee Indemnitee by any third party to the extent attributable to or resulting from a Peptide considered in isolation, the Peptides and/or the Technology (and not attributable to or resulting
from the combination of any Peptide(s) with any other substance or material (other than the Technology)), or any alleged infringement of any United States patent by any Licensor Proprietary Right. Licensor’s indemnification 

  

	***	Confidential treatment requested 

 6 

 
obligations under this Section 18.2 shall not apply to any Losses to the extent that they are directly attributable to the grossly negligent activities
or intentional misconduct of any of the Licensee Indemnitees. 
 18.3 Certain Procedures Regarding Indemnification. All
claims for indemnification under this Agreement shall be made as follows: 
 (a) In the event a third-party claim, action,
suit, or proceeding is made against a party entitled to indemnification under this Section 18 (the “Indemnitee”) for which the Indemnitee would be entitled to indemnification hereunder (a “Claim”), the Indemnitee shall
notify the Indemnitor of such Claim, specifying the nature and the amount of the Claim (the “Claim Notice”). The Claim Notice must be delivered promptly after the Indemnitee becomes aware of the Claim, provided that the failure of the
Indemnitee to comply with such requirement shall not relieve the party required to indemnify a person under Section 18 (the “Indemnitor”) of its obligations hereunder unless the Indemnitor is materially prejudiced in the defense of
the Claim due to such failure on the part of the Indemnitee. The Indemnitor shall have the right to undertake and control the defense of any Claim at its expense through counsel of its own choosing (subject to the Indemnitee’s consent to such
counsel, which consent may not be unreasonably withheld or delayed). If the Indemnitor undertakes the defense of a Claim: (i) the Indemnitor shall not permit to exist any lien, encumbrance or other adverse charge upon any asset of the
Indemnitee; (ii) the Indemnitor may not settle such action without first obtaining the written consent of the Indemnitee, which consent will not be unreasonably withheld or delayed, except for settlements solely covering monetary matters for
which the Indemnitor acknowledges responsibility for payment; and (iii) the Indemnitor shall permit the Indemnitee (at the Indemnitee’s sole cost and expense) to participate in such settlement or defense through counsel chosen by the
Indemnitee. 
 (b) The Indemnitee agrees to preserve and provide access to all evidence in its possession or control that may
be useful in defending against a Claim and to provide reasonable cooperation in the defense thereof or in the prosecution of any action against a third party in connection therewith at the Indemnitor’s expense. The Indemnitor’s defense of
any Claim or demand shall not constitute an admission or concession of liability therefor or otherwise operate in derogation of any rights the Indemnitor may have against the Indemnitee or any third party. So long as the Indemnitor is reasonably
contesting any such Claim in good faith, the Indemnitee shall not pay or settle any such Claim. 
 (c) If the Indemnitor
elects not to undertake the defense of the Claim, the Indemnitor shall notify the Indemnitee in writing of such election and the Indemnitee shall thereafter have the right to assume the defense of the Claim through counsel of its own choosing and
contest, settle or compromise the Claim in the exercise of its exclusive discretion at the expense of the Indemnitor. All reasonable expenses incurred by the Indemnitee pursuant to this Section 18.3(c) shall be reimbursed by the Indemnitor
within twenty (20) days of receipt of competent written evidence of such expenses. 
 19. Miscellaneous. 
 19.1 Amendment and Waiver. Except as otherwise expressly provided herein, any provision of this Agreement may be amended and the
observance of any provision of this Agreement may be waived (either generally or any particular instance and either retroactively or prospectively) only with the written consent of the parties. 
 19.2 Governing Law; Legal Actions; Attorneys’ Fees. This Agreement shall be governed by and construed under the laws of the
State of Washington. Subject to Section 19.3, the sole jurisdiction and venue for actions related to the subject matter hereof shall be the State of Washington state and U.S. federal courts having within their jurisdiction the location of
Licensor’s principal place of 

  

	***	Confidential treatment requested 

 7 

 
business. Both parties consent to the jurisdiction of such courts and agree that process may be served in the manner provided herein for giving of notices or
otherwise as allowed by Washington or U.S. federal law. In any action or proceeding to enforce rights under this Agreement, the prevailing party shall be entitled to recover its reasonable costs and attorneys’ fees. 
 19.3 Arbitration. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by
arbitration conducted in Seattle, Washington and administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having
jurisdiction thereof. Notwithstanding the foregoing, either party may, without waiving any remedy under this Agreement, seek from any court having jurisdiction thereof any interim or provisional relief that is necessary to protect the rights or
property of that party from immediate and irreparable injury, loss or damage. 
 19.4 Headings. Headings and captions
are for convenience only and are not to be used in the interpretation of this Agreement. 
 19.5 Notices. All notices,
requests, and other communications hereunder shall be in writing. Any notice, request, or other communication hereunder shall be deemed duly given: (a) when delivered personally to the recipient; (b) one (1) business day after being
sent to the recipient by reputable overnight courier service (charges prepaid); (c) one (1) business day after being sent to the recipient by fax; or (d) four (4) business days after being mailed to the recipient by certified or
registered mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set forth below: 
  

							
		
	If to Licensee:	  	If to Licensor:
				
	Address:	  	 111 Maiden Lane, Suite 600
 San Francisco, CA
94108
	  	Address:	  	 22118 20th Avenue SE, Suite 204
 Bothell, WA
98021

				
	Fax:	  	(415) 273-8017	  	Fax:	  	(425) 806-2999
				
	Attn:	  	 Lori Bush,
 President and General Manager
	  	Attn:	  	 Vice President, Marketing and
 Business
Development

 Either party may change the address or other contact information to which notices, requests, and other
communications hereunder are to be delivered by giving the other party notice in the manner set forth herein. 
 19.6
Entire Agreement. This Agreement supersedes all proposals, oral or written, all negotiations, conversations, or discussions between or among the parties relating to the subject matter of this Agreement and all past dealing or industry custom.

 19.7 Force Majeure. Neither party hereto shall be responsible for any failure to perform its obligations under this
Agreement (other than obligations to pay money or obligations under Section 8 (Confidentiality)) if such failure is caused by acts of God, war, strikes, lack or failure of transportation facilities, laws or governmental regulations or other
causes that are beyond the reasonable control of such party. Obligations hereunder, however, shall in no event be excused but shall be suspended only until the cessation of any cause of such failure. In the event that such force majeure 

  

	***	Confidential treatment requested 

 8 

 
should obstruct performance of this Agreement for more than six (6) months, the parties hereto shall consult with each other to determine whether this
Agreement should be modified. The party facing an event of force majeure shall use diligent commercial efforts in order to remedy that situation as well as to minimize its effects. A case of force majeure shall be notified to the other party within
5 days after its occurrence. 
 19.8 Severability. If any provision of this Agreement is held illegal, invalid or
unenforceable by a court of competent jurisdiction, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. 
 19.9 No Implied License. Each party recognizes that Licensor grants no license, by implication or otherwise, except for the
licenses expressly set forth in this Agreement. 
 19.10 Basis of Bargain. Each party recognizes and agrees that the
warranty disclaimers and liability and remedy limitations in this Agreement are material bargained for bases of this Agreement and that they have been taken into account and reflected in determining the consideration to be given by each party under
this Agreement and in the decision by each party to enter into this Agreement. 
  

									
	 LICENSEE:
  
 RODAN & FIELDS, LLC
	 		 	 LICENSOR:
  
 HELIX BIOMEDIX, INC.

					
	By:	 	/s/ Lori Bush	 		 	By:	 	/s/ Robin Carmichael
	 Name:
 Title:
	 	 Lori Bush
 President & General
Manager
	 		 	 Name:
 Title:
	 	 Robin Carmichael
 VP Marketing & Business
Development

					
	Date:	 	27 August, 2008	 		 	Date:	 	27 August, 2008

  

	***	Confidential treatment requested 

 9 

 EXHIBIT A 
 TECHNOLOGY 
 Licensor’s Pip3TM Technology for protease inhibition 
 *** 
  

	***	Confidential treatment requested2006 Equity Incentive Award Plan Form of Restricted Stock Unit Agreement

 Exhibit 10.58 
 BARE ESCENTUALS, INC. 
 2006 EQUITY INCENTIVE AWARD PLAN 
 RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 
 Bare Escentuals, Inc., a Delaware corporation (the
“Company”), pursuant to its 2006 Equity Incentive Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), an award of restricted stock units
(“Restricted Stock Units” or “RSUs”) with respect to the number of shares of the Company’s common stock, par value $0.001 (the “Shares”). This award for Restricted Stock
Units (this “RSU Award”) is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “Restricted Stock Unit
Agreement”) and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Restricted Stock Unit
Agreement. 
  

			
	 Participant:
	  	 
		
	 Grant Date:
	  	 
		
	 Vesting Commencement Date:
	  	 
		
	 Total Number of RSUs Subject to Award:
	  	 
		
	 Vesting Schedule:
	  	 
		
	 Distribution Schedule:
	  	The RSUs shall be distributable as they vest pursuant to the Vesting Schedule.

 By his or her signature and the Company’s signature below, Participant agrees to be bound by
the terms and conditions of the Plan, the Restricted Stock Unit Agreement and this Grant Notice. Participant has reviewed the Restricted Stock Unit Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the
advice of counsel prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Restricted Stock Unit Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Committee upon any questions arising under the Plan, this Grant Notice or the Restricted Stock Unit Agreement. 
  

									
	BARE ESCENTUALS, INC.	 		 	PARTICIPANT
					
	By:	 	 	 		 	By:	 	 
	Print Name:	 	 	 		 	Print Name:	 	 
	Title:	 	 	 		 		 	
	Address:	 	71 Stevenson Street, 22nd Floor	 		 	Address:	 	 
		 	San Francisco, CA 94105	 		 		 	 

 EXHIBIT A 
 TO RESTRICTED STOCK UNIT AWARD GRANT NOTICE 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 

Pursuant to the Restricted Stock Unit Award Grant Notice (the “Grant Notice”) to which this Restricted Stock Unit Award
Agreement (this “Agreement”) is attached, the Company has granted to Participant the right to receive the number of RSUs set forth in the Grant Notice, subject to all of the terms and conditions set forth in this Agreement,
the Grant Notice and the Plan. The RSU Award and this Agreement are subject to the Plan, the terms and conditions of which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the
Plan shall control. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice. 
 ARTICLE I. 
 AWARD OF RESTRICTED STOCK UNITS 
 1.1 Award of Restricted Stock Units. 
 (a) Award. In consideration of Participant’s past and/or continued employment with or service to the Company or any parent or subsidiary thereof and for other good and valuable consideration, the Company
hereby grants to Participant the right to receive the number of RSUs set forth in the Grant Notice, subject to all of the terms and conditions set forth in this Agreement, the Grant Notice and the Plan. Each RSU represents the right to receive one
Share. Prior to actual issuance of any Shares, the RSUs and the RSU Award represent an unsecured obligation of the Company, payable only from the general assets of the Company. 
 (b) Vesting. The RSUs subject to the RSU Award shall vest in accordance with the Vesting Schedule set forth in the Grant Notice.
Unless and until the RSUs have vested in accordance with the vesting schedule set forth in the Grant Notice, Participant will have no right to any distribution with respect to such RSUs. In the event of Participant’s termination of service as
an Employee, Non-Employee Director or Consultant prior to the vesting of all of the RSUs, any unvested RSUs will terminate automatically without any further action by the Company and be forfeited without further notice and at no cost to the Company.
Participant shall not be deemed to have a termination of service merely because of a change in the capacity in which Participant renders service to the Company or any Subsidiary or a change in the entity for which Participant renders such service,
unless following such change in capacity or service Participant is no longer serving as an Employee, Non-Employee Director or consultant of the Company or any Subsidiary. 
 (c) Distribution of Shares. 
 (i) Shares of Stock shall be distributed to Participant (or in the event of Participant’s death, to his or her estate) with respect to such Participant’s vested RSUs on each vesting date as the RSU vests
pursuant to the Vesting Schedule set forth in the Grant Notice, subject to the terms and provisions of the Plan and this Agreement. 
 (ii) All distributions shall be made by the Company in the form of whole shares of Stock. 
  

 A-1 

 (iii) Notwithstanding the foregoing, shares of Stock shall be issuable pursuant to an RSU
at such times and upon such events as are specified in this Agreement only to the extent issuance under such terms will not cause the RSUs or the shares of Stock issuable pursuant to the RSUs to be includible in the gross income of Participant under
Section 409A of the Code prior to such times or the occurrence of such events, as permitted by the Code and the regulations and other guidance thereunder. 
 (d) Generally. Shares issued under the RSU Award shall be issued to Participant or Participant’s beneficiaries, as the case
may be, at the sole discretion of the Committee, in either (a) uncertificated form, with the Shares recorded in the name of Participant in the books and records of the Company’s transfer agent with appropriate notations regarding the
restrictions on transfer imposed pursuant to this Agreement; or (b) certificate form. 
 1.2 Tax Withholding; Conditions to Issuance
of Shares. Notwithstanding any other provision of this Agreement (including, without limitation, Section 1.1(b) hereof): 
 (a) Tax Withholding. 
 (i) The Company has the authority to deduct or withhold, or require Participant to
remit to the Company, an amount sufficient to satisfy applicable Federal, state, local and foreign taxes (including any FICA obligation) required by law to be withheld with respect to any taxable event arising from the receipt of the Shares upon
settlement of the RSUs. To the maximum extent permitted by law, the Company has the right to retain, without notice, from Shares issuable under the RSU Award or from other compensation payable to Participant, shares of Stock or cash having a value
sufficient to satisfy Participant’s tax withholding obligation. 
 (ii) At any time not less than five business days
before any such tax withholding obligation arises, Participant may elect to satisfy his or her tax obligation, in whole or in part, by either: (A) electing to have the Company withhold from other cash compensation payable to Participant or
Shares otherwise to be delivered to Participant pursuant to the RSU Award with a Fair Market Value equal to the minimum amount of the tax withholding obligation, or (B) paying the amount of the tax withholding obligation directly to the Company
in cash. Unless Participant chooses to satisfy his or her tax withholding obligation in accordance with clause (B) above, Participant’s tax withholding obligation may be automatically satisfied in accordance with clause (A) above. The
Committee will have the right to disapprove an election to pay Participant’s tax withholding obligation under clause (B) in its sole discretion. In the event Participant’s tax withholding obligation will be satisfied under clause
(A) above, then the Company, upon approval of the Committee, may elect (in lieu of withholding the applicable withholding taxes from other cash compensation payable to Participant or Shares to be delivered to Participant pursuant to the RSU
Award) to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on Participant’s behalf a whole number of shares from those Shares issuable to Participant upon settlement of the RSUs as the Company determines
to be appropriate to generate cash proceeds sufficient to satisfy Participant’s tax withholding obligation. Participant’s acceptance of this RSU Award constitutes Participant’s instruction and authorization to the Company and such
brokerage firm to complete the transactions described in clause (A) above, including the transactions described in the previous sentence, as applicable. Any Shares to be sold at the Company’s direction through a broker-assisted sale will
be sold on the day the tax withholding obligation arises (i.e., the date Stock is delivered) or as soon thereafter as practicable. The Shares may be sold as part of a block trade with other participants of the Plan in which all participants receive
an average price. Participant will be responsible for all broker’s fees and other costs of sale, and Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. To the
extent the proceeds of such sale exceed Participant’s tax withholding obligation, the Company agrees to pay such excess in cash to Participant as soon as practicable. Participant acknowledges that the Company or its designee is under no
obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy Participant’s tax withholding obligation. The Company may refuse to issue any Shares in settlement of the RSU
Award to Participant until the foregoing tax withholding obligations are satisfied. 
  

 A-2 

 (b) Conditions to Issuance of Shares. The Company shall not be required to issue
or deliver any Shares issuable upon the vesting of the RSUs prior to the fulfillment of all of the following conditions: (i) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (ii) the
completion of any registration or other qualification of the Shares under any state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or other governmental regulatory body, which the Committee shall, in
its sole and absolute discretion, deem necessary and advisable, (iii) the obtaining of any approval or other clearance from any state or federal governmental agency that the Committee shall, in its absolute discretion, determine to be necessary
or advisable, (iv) the lapse of any such reasonable period of time following the date the RSUs vest as the Committee may from time to time establish for reasons of administrative convenience and (v) the receipt by the Company of full
payment of any applicable withholding tax in any manner permitted under Section 1.2(a) above. 
 ARTICLE II. 
 OTHER PROVISIONS 
 2.1 RSU Award
and Interests Not Transferable. This RSU Award and the rights and privileges conferred hereby, including the RSUs awarded hereunder, shall not be liable for the debts, contracts or engagements of Participant or his or her successors in interest
or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or
any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect. 
 2.2 Rights as Stockholder. Neither Participant nor any person claiming under or through Participant shall have any of the rights or privileges of a shareholder of the Company in respect of any Shares issuable hereunder unless and
until certificates representing such Shares (which may be in uncertificated form) will have been issued and recorded on the books and records of the Company or its transfer agents or registrars, and delivered to Participant (including through
electronic delivery to a brokerage account). After such issuance, recordation and delivery, Participant shall have all the rights of a stockholder of the Company, including with respect to the right to vote the Shares and the right to receive any
cash or share dividends or other distributions paid to or made with respect to the Shares. 
 2.3 Not a Contract of Employment or other
Service Relationship. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as an employee or other service provider of the Company or any of its affiliates. 
 2.4 Construction. This Agreement shall be administered, interpreted and enforced under the laws of the State of Delaware without regard to
conflicts of laws thereof. Should any provision of this Agreement be determined by a court of law to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable. 
 2.5 Conformity to Securities Laws. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with
all provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the U.S. Securities and Exchange Commission, including, without limitation, Rule 16b-3 under the Exchange Act. 

  

 A-3 

 
Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Awards are granted, only in such a manner as to conform to such
laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 
 2.6 Amendment, Suspension and Termination. This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by
Participant and by a duly authorized representative of the Company. 
 2.7 Notices. Any notice to be given under the terms of this
Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the address given beneath the signature of an authorized officer of the Company on the Grant Notice, and any notice to be given to Participant
shall be addressed to Participant at the address given beneath Participant’s signature on the Grant Notice. By a notice given pursuant to this Section 2.7, either party may hereafter designate a different address for notices to be given to
that party. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States
Postal Service. 
 2.8 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple
assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Participant and his or her heirs, executors,
administrators, successors and assigns. 
 2.9 Section 409A. This
Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the amounts payable hereunder shall be paid no later than the later of: (a) the fifteenth (15th) day of the third month following Executive’s first taxable year in which such severance benefit is no longer subject to a substantial risk of
forfeiture, and (b) the fifteenth (15th) day of the third month following first taxable year of the Company in which such severance
benefit is no longer subject to substantial risk of forfeiture, as determined in accordance with Section 409A of the Code and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be
interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder. 
 2.10 Tax Representations. Participant has reviewed with Participant’s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by the
Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Participant understands that Participant (and not the Company) shall be responsible for
Participant’s own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 
  

 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]